
Eduard V Karamov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7737231/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Antiseptic Polymer–Surfactant Complexes with Long-Lasting Activity against SARS-CoV-2. Polymers, 2022, 14, 2444.	2.0	5
2	Cationic Surfactants as Disinfectants against SARS-CoV-2. International Journal of Molecular Sciences, 2022, 23, 6645.	1.8	14
3	Antiviral activity of natural humic substances and shilajit materials against HIV-1: Relation to structure. Environmental Research, 2021, 193, 110312.	3.7	26
4	Phosphoramidate conjugates of 3′-azido-3′-deoxythymidine glycerolipid derivatives and amino acid esters: synthesis and anti-HIV activity. Medicinal Chemistry Research, 2021, 30, 664-671.	1.1	2
5	A New Approach to Developing Long-Acting Injectable Formulations of Anti-HIV Drugs: Poly(Ethylene) Tj ETQq1 I International Journal of Molecular Sciences, 2021, 22, 340.	0.784314 1.8	⊦rgBT /Overla 3
6	Switching to dual therapy after 24 weeks of the triple therapy of HIV infection: efficacy and safety. Infectious Diseases: News, Opinions, Training, 2021, 10, 66-75.	0.1	0
7	Spectroscopic, Zeta-potential and Surface Plasmon Resonance analysis of interaction between potential anti-HIV tannins with different flexibility and human serum albumin. Colloids and Surfaces B: Biointerfaces, 2020, 194, 111175.	2.5	17
8	Species diversity of non-tuberculous mycobacteria isolated from HIV-positive and HIV-negative patients. , 2020, , .		0
9	Induction of M. tuberculosis (MTB) drug resistance (DR) mutations in HIV-infected hosts and pathways of further spread of the evolutionary successful drug-resistant MTB clonal lines. , 2020, , .		0
10	Comparison of susceptibility testing results of MAC isolated from HIV-positive andHIV-negative patients. , 2020, , .		0
11	Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis. Lancet Infectious Diseases, The, 2019, 19, 143-155.	4.6	255
12	The Differential Anti-HIV Effect of a New Humic Substance-Derived Preparation in Diverse Cells of the Immune System. Acta Naturae, 2019, 11, 68-76.	1.7	6
13	HIV-1 Genetic Diversity in Recently Diagnosed Infections in Moscow: Predominance of A _{FSU} , Frequent Branching in Clusters, and Circulation of the Iberian Subtype G Variant. AIDS Research and Human Retroviruses, 2018, 34, 629-634.	0.5	16
14	102 HIV/AIDS vaccines in Russia. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 39.	0.9	1
15	101 Biomedical Prevention of HIV/AIDS in Russia. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 39.	0.9	0
16	Humic Acids (HA) Strongly Potentiate Anti-HIV Effects of AZT, Griffithsin, and Cyanovirin. AIDS Research and Human Retroviruses, 2014, 30, A204-A204.	0.5	1
17	Porous silicon nanoparticles as scavengers of hazardous viruses. Journal of Nanoparticle Research, 2014, 16, 1.	0.8	51
18	The Analysis of Near Full-Length Genome Sequences of HIV Type 1 Subtype A Viruses from Russia Supports the Monophyly of Major Intrasubtype Clusters. AIDS Research and Human Retroviruses, 2012, 28, 1340-1343	0.5	9

Eduard V Karamov

#	Article	IF	CITATIONS
19	The Situation of HIV/M. tuberculosis Co-Infection in Russia. The Open Infectious Diseases Journal, 2011, 5, 36-50.	0.6	1
20	Research Priorities for HIV/M. tuberculosis Co-Infection. The Open Infectious Diseases Journal, 2011, 5, 14-20.	0.6	0
21	Novel herpes simplex virus and human immunodeficiency virus inhibitors based on phosphonate nucleoside analogs. Moscow University Chemistry Bulletin, 2008, 63, 85-88.	0.2	1
22	trans-Dihydroxypiperidines: Synthesis, Stereochemistry, and Anti-HIV Activity. Doklady Chemistry, 2003, 391, 195-199.	0.2	4
23	Variability Analysis of HIV-1 gp120 V3 Region: IV. Distribution Functions for Intra- and Inter- Subtype Amino Acid Hamming Distances. Journal of Biomolecular Structure and Dynamics, 1998, 15, 877-885.	2.0	2
24	One-parameter Discrete Model of the Genetic Diversity. Journal of Biomolecular Structure and Dynamics, 1998, 15, 887-894.	2.0	2
25	Sequence Note: Extreme Founder Effect in an HIV Type 1 Subtype A Epidemic among Drug Users in Svetlogorsk, Belarus. AIDS Research and Human Retroviruses, 1998, 14, 1299-1303.	0.5	51
26	Dependencies of Substitution Steps Number on Hamming Distance Are Identical For One-parameter Discrete Models of Both Direct and Parallel Genetic Diversity. Journal of Biomolecular Structure and Dynamics, 1998, 16, 133-138.	2.0	2
27	Variability Analysis of HIV-1 gp120 V3 Region: II. Hierarchy of Taxons. Journal of Biomolecular Structure and Dynamics, 1997, 15, 231-241.	2.0	6
28	Variability Analysis of HIV-1 gp120 V3 Region: I. Point Estimators for the Amino Acid Distribution Characteristics. Journal of Biomolecular Structure and Dynamics, 1997, 15, 217-229.	2.0	6
29	Variability Analysis of HIV-1 gp120 V3 Region: III. Distinctions Between Various Sets of Peptide Fragments Derived From the Sequences Belonging to Different HIV-1 Taxons. Journal of Biomolecular Structure and Dynamics, 1997, 15, 537-546.	2.0	3
30	Quantitative PCR as a method for monitoring retroviral infection on the gene level. Virus Genes, 1995, 10, 45-51.	0.7	1
31	Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Penetration into Target Cells by Synthetic Peptides Mimicking the N-Terminus of the HIV-1 Transmembrane Glycoprotein. Virology, 1993, 194, 294-301.	1.1	38
32	CD4-derived peptide and sulfated polysaccharides have similar mechanisms of anti-HIV activity based on electrostatic interactions with positively charged gp120 fragments. Molecular Immunology, 1993, 30, 993-1001.	1.0	21
33	Investigation of Human Immunodeficiency Virus Fusion Peptides. Analysis of Interrelations Between Their Structure and Function. AIDS Research and Human Retroviruses, 1992, 8, 9-18.	0.5	54
34	Interaction of human immunodeficiency virus (HIV-1) fusion peptides with artificial lipid membranes. Biochemical and Biophysical Research Communications, 1990, 172, 952-957.	1.0	45
35	False-positive sera do not react with human immunodeficiency virus (HIV)Gag-encoded recombinant antigen. Journal of Medical Virology, 1989, 27, 72-75.	2.5	6
36	Detection by immunogold techniques of hiv antigens in lowicryl ultrathin sections of infected cells. Pathology Research and Practice, 1989, 184, 494-497.	1.0	2

EDUARD V KARAMOV

#	Article	IF	CITATIONS
37	Recombinant env protein in diagnosis of AIDS. Bulletin of Experimental Biology and Medicine, 1988, 105, 689-691.	0.3	Ο
38	Peptide mapping of human adenovirus type 6 and simian adenovirus type 7 hexon and core protein. Bulletin of Experimental Biology and Medicine, 1981, 91, 322-324.	0.3	0
39	Analysis of DNA from human adenovirus type 6 with restriction endonucleases HindIII, BglIII and BamHI. Nucleic Acids and Protein Synthesis, 1980, 606, 214-227.	1.7	7
40	EcoRla activity: Enzyme modification or activation of accompanying endonuclease?. Gene, 1978, 4, 195-212.	1.0	46
41	Analysis of the genome of type 7 simian adenovirus using restrictases. Nucleic Acids Research, 1978, 5, 999-1012.	6.5	9
42	Transformation of substrate specificity of EcoRl restrictase by glycerol. Bulletin of Experimental Biology and Medicine, 1977, 84, 973-975.	0.3	0